Keyphrases
High Mobility Group Box 1 (HMGB1)
100%
Inflammatory Pathways
100%
Advanced Glycation End Products
100%
Receptor for Advanced Glycation End Products
100%
Trimebutine
100%
Papaverine
57%
Suppression Effect
42%
Inflammatory Cytokines
28%
Extracellular Signal-regulated Kinase 1/2
28%
Macrophage-like
14%
Tumor Necrosis Factor-α
14%
RAW264.7 Cells
14%
Inflammation
14%
Macrophages
14%
Interleukin-6
14%
Inflammatory Diseases
14%
Inhibitory Effect
14%
Induced Production
14%
Mouse Bone Marrow
14%
Mechanism of Action
14%
Intracellular Domain
14%
Tail Domain
14%
Dual Inhibitor
14%
3D Pharmacophore
14%
Action Analysis
14%
C-Jun N-terminal Protein Kinase
14%
Extracellular Interactions
14%
Medicine and Dentistry
Advanced Glycation End-Product
100%
Cell Signaling Pathway
100%
Advanced Glycation End Product Receptor
100%
Trimebutine
100%
Papaverine
57%
Macrophage
28%
Phosphotransferase
28%
Inflammatory Cytokine
28%
Mitogen Activated Protein Kinase 3
28%
Mitogen Activated Protein Kinase 1
28%
Upregulation
14%
Interleukin 6
14%
Tumor Necrosis Factor
14%
Amino Terminal Sequence
14%
Mediator
14%
Tail
14%
Inflammatory Disorder
14%
Kinase
14%
Pharmacophore
14%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Glycation End Product
100%
Advanced Glycation End Product Receptor
100%
Trimebutine
100%
Papaverine
57%
Mitogen Activated Protein Kinase 3
28%
Cytokine
28%
Phosphotransferase
28%
Mitogen Activated Protein Kinase 1
28%
Tumor Necrosis Factor
14%
Inflammation
14%
Inflammatory Disease
14%
Interleukin 6
14%
Immunology and Microbiology
Glycation
100%
Macrophage
25%
Proinflammatory Cytokine
25%
Tumor Necrosis Factor
12%
Upregulation
12%
Interleukin 6
12%
Mediator
12%
Inflammatory Disorder
12%
Amino Terminal Sequence
12%
Pharmacophore
12%